BioMarin snaps up Amicus Therapeutics for $4.8bn amid uncommon illness push
BioMarin Pharmaceutical has agreed to purchase uncommon illness biotech Amicus Therapeutics, including three accepted or late-stage lysosomal storage dysfunction therapies to its portfolio.
Underneath the phrases of the settlement, BioMarin can pay money for all of Amicus’ shares for a complete consideration of $4.8bn. This deal will set BioMarin again $14.50 per share, constituting a 33% premium on Amicus’ $10.89 18 December inventory worth at market shut.
Uncover B2B Advertising That Performs
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
BioMarin’s inventory has elevated 17.71% on the acquisition, from an 18 December shut of $51.95 to a 19 December shut of $61.15.
This multi-billion-dollar deal, which is the largest in BioMarin’s historical past, will give the pharma rights to Amicus’ Fabry illness remedy, Galafold (migalastat), which has been on the US market since 2018. In 2024, the drug introduced in $458.1m for Amicus, an 18% improve on 2023.
Galafold is presently the one US Meals and Drug Administration (FDA) accepted chaperone remedy for Fabry illness – a uncommon genetic dysfunction characterised by the buildup of fatty substrates within the cells of an affected affected person.
Following a US patent litigation with generics big Teva Prescription drugs, Galafold now holds market exclusivity till January 30, 2027.
BioMarin may even purchase the rights to Amicus’ FDA-approved Pompe illness mixture, Pombiliti (cipaglucosidase alfa-atga) plus Opfolda (miglustat), which acquired the FDA go-ahead to be used in sufferers who are usually not responding to straightforward enzyme substitute remedy again in 2023. The drug generated $22m in 2024.
Like Fabre illness, Pompe illness is a lysosomal storage dysfunction that forestalls the metabolism of glycogen, resulting in its dangerous buildup inside the cells. This may result in progressive muscular weak spot and coronary heart issues.
Alongside these accepted therapies, BioMarin will take possession of the US rights to the late-stage, investigational oral small molecule, DMX-200, which is presently in Part III trials for uncommon kidney illness, focal segmental glomerulosclerosis (FSCS). Amicus initially bought the US rights to DMX-200 from the drug’s creator, Dimerix, for as much as $105m in Might 2025.
BioMarin eyes future development
During the last couple of years, BioMarin has been seeking to additional its development within the pharmaceutical sector.
In a bid to attain this, the corporate underwent a important restructuring in 2024, which noticed it let go of 225 staff.
Transferring into 2025, BioMarin has employed a powerful dealmaking technique, which noticed the corporate signal 10 offers in 2025. In line with GlobalData’s Pharmaceutical Intelligence Middle, that is the best variety of offers to be signed in a single 12 months since 2010.
One of many extra distinguished offers was BioMarin’s acquisition of Inozyme, which set it again $270m, whereas including Inozyme’s late-stage enzyme substitute remedy, INZ-701, to its pipeline.
Following its merger with Amicus, BioMarin famous that each Galafold and Pombiliti-Opfolda have “excessive development potential,” that means the acquisition might additional speed up the corporate’s income development shifting ahead.
This might be additional supported by the enlargement of Galafold and Pombiliit-Opfolda’s international footprint, which BioMarin talked about as a chance in a 19 December assertion.
Analysts at GlobalData, guardian firm of Pharmaceutical Expertise, presently forecast that Galafold will generate gross sales of $840m in 2031, whereas Pombiliti-Opfolda is predicted to herald $691m throughout the identical 12 months.
Join our every day information round-up!
Give your enterprise an edge with our main trade insights.
